

Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure

Gunnar H. Gislason, MD, PhD; Jeppe N. Rasmussen, MD, PhD; Steen Z. Abildstrom, MD, PhD; Tina K. Schramm, MD; Morten L. Hansen, MD; Emil L. Fosbøl, MB; Rikke Sørensen, MD; Fredrik Folke, MD; Pernille Buch, MD, PhD; Niels Gadsbøll, MD, DMSc; Søren Rasmussen, MSc, PhD; Henrik E. Poulsen, MD, DMSc; Lars Køber, MD, DMSc; Mette Madsen, MSc; Christian Torp-Pedersen, MD, DMSc

Background: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF.

Methods: We identified 107 092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models.

Results: A total of 36 354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60 974 (56.9%)

died, and 8970 (8.4%) and 39 984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results.

Conclusions: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.

Arch Intern Med. 2009;169(2):141-149

SINCE PUBLICATION OF THE Vioxx Gastrointestinal Outcomes Research (VIGOR) Study in 2000,¹ debate has been ongoing about increased cardiovascular risk of nonsteroidal anti-inflammatory drugs (NSAIDs), in particular, the selective cyclooxygenase-2 (COX-2) inhibitors.²⁻¹¹ Clinical guidelines discourage use of NSAIDs in patients with chronic heart failure (HF) owing to increased risk of fluid retention and worsening of HF.^{12,13} Recent recommendations from the American Heart Association¹⁴ are to avoid administration of selective COX-2 inhibitors in patients with established or increased risk of cardiovascular disease and to consider alternative pain medications before using NSAIDs in this population. Patients receiving NSAIDs are often elderly, frequently have other concurrent medical

illnesses, and often have multiple cardiovascular risk factors or established cardiovascular disease. Furthermore, many NSAIDs are sold over the counter (OTC) in pharmacies and convenience stores without expert advice about their use and potential drug interactions or adverse effects, which might give the misconception that NSAIDs are harmless.

The widespread use of NSAIDs and the perception of low risk associated with such OTC drugs prompted us to study an unselected cohort of 107 092 patients surviving a first hospitalization because of HF, with particular focus on risk of death and hospitalization as a result of the use of NSAIDs.

The Danish Data Protection Agency approved this study (No. 2003-54-1269). No ethical approval is required for retrospective registry studies in Denmark.

Author Affiliations are listed at the end of this article.

Table 1. Baseline Characteristics of the Study Sample According to Exposure Group

| Characteristic | Total Population, No. (%) | Treatment Group, No. (%) | | | | | | |
|--|---------------------------|--------------------------|-------------|-------------|---------------|-------------|-------------|---------------|
| | | No NSAID | Rofecoxib | Celecoxib | Ibuprofen | Diclofenac | Naproxen | Other NSAIDs |
| Total No. of patients | 107 092 | 70 738 (66.1) | 6116 (5.7) | 5734 (5.4) | 16 975 (15.8) | 9377 (8.8) | 2176 (2.0) | 11 488 (10.7) |
| Age, mean (SD), y | 74.8 (11.6) | 75.5 (11.5) | 75.2 (10.8) | 74.6 (10.8) | 72.1 (12.1) | 71.7 (11.9) | 72.2 (12.0) | 73.9 (11.2) |
| Sex | | | | | | | | |
| Male | 55 368 (51.7) | 36 854 (52.1) | 2603 (42.6) | 2445 (42.6) | 9237 (54.4) | 5170 (55.1) | 1253 (57.6) | 5488 (47.8) |
| Female | 51 724 (48.3) | 33 884 (47.9) | 3513 (57.4) | 3289 (57.4) | 7738 (45.6) | 4207 (44.9) | 923 (42.4) | 6000 (52.2) |
| Year of first hospitalization because of HF | | | | | | | | |
| 1995-1996 | 19 789 (18.5) | 11 924 (16.9) | 780 (12.8) | 619 (10.8) | 4345 (25.6) | 2226 (23.7) | 723 (33.2) | 3148 (27.4) |
| 1997-1998 | 19 996 (18.6) | 12 300 (17.4) | 1131 (18.5) | 920 (16.0) | 3817 (22.5) | 2254 (24.1) | 497 (22.8) | 2792 (24.3) |
| 1999-2000 | 22 588 (21.1) | 13 882 (19.6) | 1937 (31.7) | 1702 (29.7) | 3865 (22.8) | 2269 (24.2) | 472 (21.7) | 2601 (22.6) |
| 2001-2002 | 23 257 (21.7) | 15 284 (21.6) | 1761 (28.8) | 1770 (30.9) | 3211 (18.9) | 1791 (19.1) | 328 (15.1) | 1901 (16.5) |
| 2003-2004 | 21 462 (20.1) | 17 348 (24.5) | 507 (8.3) | 723 (12.6) | 1727 (10.2) | 837 (8.9) | 156 (7.2) | 1046 (9.1) |
| Comorbidity ^a | | | | | | | | |
| MI | 14 638 (13.7) | 10 040 (14.2) | 747 (12.2) | 721 (12.6) | 2170 (12.8) | 1226 (13.1) | 259 (11.9) | 1393 (12.1) |
| Peripheral vascular disease | 2736 (2.6) | 1967 (2.8) | 114 (1.9) | 117 (2.0) | 348 (2.1) | 190 (2.0) | 37 (1.7) | 242 (2.1) |
| Cerebrovascular disease | 7982 (7.5) | 5770 (8.2) | 385 (6.3) | 380 (6.6) | 941 (5.5) | 519 (5.5) | 98 (4.5) | 663 (5.8) |
| COPD | 16 534 (15.4) | 11 023 (15.6) | 933 (15.3) | 900 (15.7) | 2577 (15.2) | 1415 (15.1) | 307 (14.1) | 1695 (14.7) |
| Peptic ulcer disease | 3638 (3.4) | 2644 (3.7) | 247 (4.0) | 216 (3.8) | 321 (1.9) | 239 (2.6) | 46 (2.1) | 336 (2.9) |
| Diabetes mellitus | 13 070 (12.2) | 8723 (12.3) | 680 (11.1) | 711 (12.4) | 2088 (12.3) | 1043 (11.1) | 229 (10.5) | 1352 (11.8) |
| Diabetes mellitus with chronic complications | 5862 (5.5) | 4051 (5.7) | 284 (4.6) | 297 (5.2) | 856 (5.0) | 417 (4.5) | 87 (4.0) | 560 (4.9) |
| Renal disease | 3364 (3.1) | 2571 (3.6) | 127 (2.1) | 93 (1.6) | 392 (2.3) | 151 (1.6) | 34 (1.6) | 260 (1.9) |
| Rheumatologic disease | 1827 (1.7) | 1026 (1.5) | 212 (3.5) | 191 (3.3) | 277 (1.6) | 146 (1.6) | 35 (1.6) | 207 (1.8) |
| Mild liver disease | 807 (0.8) | 571 (0.8) | 46 (0.8) | 32 (0.6) | 104 (0.6) | 64 (0.7) | 15 (0.7) | 65 (0.6) |
| Moderate or severe liver disease | 40 (0.04) | 30 (0.04) | 1 (0.02) | 0 | 3 (0.02) | 4 (0.04) | 0 | 3 (0.03) |
| Any malignant tumor | 3604 (3.4) | 2627 (3.7) | 148 (2.4) | 143 (2.5) | 437 (2.6) | 222 (2.4) | 58 (2.7) | 266 (2.3) |
| Metastatic tumor | 537 (0.5) | 410 (0.6) | 17 (0.3) | 20 (0.4) | 57 (0.3) | 31 (0.3) | 11 (0.5) | 32 (0.3) |
| Hemiplegia or paraplegia | 128 (0.1) | 93 (0.1) | 3 (0.05) | 3 (0.05) | 17 (0.1) | 11 (0.1) | 2 (0.1) | 11 (0.1) |
| Dementia | 82 (0.1) | 60 (0.1) | 4 (0.07) | 4 (0.07) | 8 (0.05) | 5 (0.05) | 0 | 6 (0.05) |
| AIDS | 36 (0.03) | 25 (0.04) | 2 (0.03) | 3 (0.05) | 6 (0.04) | 2 (0.02) | 0 | 3 (0.03) |
| Charlson Comorbidity Index score, mean (SD) | 0.8 (1.2) | 0.9 (1.3) | 0.8 (1.1) | 0.8 (1.2) | 0.7 (1.1) | 0.7 (1.1) | 0.7 (1.0) | 0.7 (1.1) |
| Severity group ^b | | | | | | | | |
| 1 | 26 543 (24.8) | 18 814 (26.6) | 1281 (20.9) | 1265 (22.1) | 3669 (21.6) | 2088 (22.3) | 443 (20.4) | 2322 (20.2) |
| 2 | 42 547 (39.7) | 26 228 (37.1) | 2804 (45.9) | 2615 (45.6) | 7658 (45.1) | 4264 (45.5) | 940 (43.2) | 5188 (45.2) |
| 3 | 24 817 (23.2) | 15 927 (22.5) | 1500 (24.5) | 1406 (24.5) | 4099 (24.2) | 2207 (23.5) | 585 (26.9) | 2848 (24.8) |
| 4 | 13 185 (12.3) | 9769 (13.8) | 531 (8.7) | 448 (7.8) | 1549 (9.1) | 818 (8.7) | 208 (9.6) | 1130 (9.8) |
| Concomitant therapy | | | | | | | | |
| β-Blocker ^c | 29 084 (27.2) | 19 041 (26.9) | 1754 (28.7) | 1762 (30.7) | 5611 (27.2) | 2679 (28.6) | 562 (25.8) | 2946 (25.6) |
| ACE inhibitors or ARBs ^c | 46 191 (44.1) | 29 645 (41.9) | 2774 (45.4) | 2601 (45.4) | 7782 (45.8) | 4404 (47.0) | 1022 (47.0) | 5137 (44.7) |
| Spironolactone ^c | 20 166 (18.8) | 13 892 (19.6) | 1079 (17.6) | 1108 (19.3) | 2778 (16.4) | 1549 (16.5) | 335 (15.4) | 1820 (15.8) |
| Statins ^d | 13 084 (12.2) | 8611 (12.2) | 714 (11.7) | 748 (13.0) | 2185 (12.9) | 1211 (12.9) | 240 (11.0) | 1218 (10.6) |
| Antidiabetes agents ^e | 13 387 (12.5) | 8843 (12.5) | 715 (11.7) | 752 (13.1) | 2187 (12.9) | 1134 (12.1) | 246 (11.3) | 1411 (12.3) |
| Loop diuretic agents ^e | 86 636 (80.9) | 57 050 (80.7) | 5008 (81.9) | 4627 (80.7) | 13 725 (80.9) | 7556 (80.6) | 1784 (82.0) | 9451 (82.3) |

Abbreviations: ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-2 receptor blockers; COPD, chronic obstructive pulmonary disease; HF, heart failure; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug.

^aAs specified by the Charlson Comorbidity Index.

^bMean daily dosage of loop-diuretic (furosemide) first 90 days from start of treatment: (group 1, 0-39 mg; group 2, 40-80 mg; group 3, 81-160 mg; and group 4, >160 mg).

^cAt least 1 prescription claimed within 90 days after discharge.

^dAt least 1 prescription claimed within 180 days after discharge.

^eAt least 1 prescription claimed between 90 days before admission and 90 days after discharge.

METHODS

POPULATION

Patients aged 30 years or older who between January 1, 1995, and December 31, 2004, survived their first hospitalization because of HF (*International Classification of Diseases, Tenth Revision*, codes I11.0, I50, I42, and J81 as primary or secondary diagnoses) were identified in the Danish National Patient Registry, which includes records of all hospitalizations in Denmark since 1978. The selection of patients and their characteristics have been described in detail previously.¹⁵ Each patient's vital status as of December 31, 2004, was obtained from the Central Population Registry.

DRUG TREATMENT

The Danish Registry of Medicinal Product Statistics, a national prescription registry, comprises all prescriptions dispensed from Danish pharmacies since 1995, which are directly and automatically linked to reimbursement of medication expenses, ensuring complete registration. Coding is according to the Anatomical Therapeutic Chemical (ATC) Classification System. The national prescription registry does not include information about prescribed daily dosage of medications. Therefore, by calculating mean dosages from up to 3 consecutive prescriptions, the daily dosage was estimated for each new prescription claim. In cases in which only 1 prescription was available, the mean dosage was the minimum predefined dos-

Table 2. Treatment and Outcome According to Exposure Group

| Drug | Patients, No. (%) | Median (Interquartile Range) | | | Duration of Exposure to Drug, Person-Years | Risk (95% CI) | | |
|---------------------------------|-------------------|--|--------------------------|-------------------|--|------------------------------|------------------------|---------------------------|
| | | Dose, Median (Interquartile Range), mg | Duration of Treatment, d | No. of Deaths | | Deaths per 1000 Person-Years | Absolute Risk Increase | NNH ^a per Year |
| Rofecoxib | 6116 (5.7) | 25 (12.5 to 25) | 42 (14 to 154) | 826 ^b | 2513 | 329 (310 to 347) | 11.1 (9.3 to 13) | 9 (8 to 11) |
| Celecoxib | 5734 (5.4) | 200 (200 to 200) | 60 (20 to 197) | 768 ^b | 2666 | 288 (271 to 305) | 7 (5.3 to 8.8) | 14 (11 to 19) |
| Ibuprofen | 16 975 (15.8) | 600 (400 to 1200) | 97 (30 to 211) | 2214 | 9366 | 236 (228 to 245) | 1.9 (1 to 2.8) | 53 (36 to 100) |
| Diclofenac | 9377 (8.8) | 75 (50 to 100) | 40 (20 to 108) | 998 ^b | 3242 | 308 (292 to 324) | 9 (7.4 to 10.6) | 11 (9 to 13) |
| Naproxen | 2176 (2.0) | 500 (500 to 550) | 64 (25 to 179) | 243 ^b | 1024 | 237 (211 to 263) | 2 (-0.6 to 4.6) | 51 (22 to 158) |
| Other NSAIDs | 11 488 (10.7) | ... | 56 (20 to 150) | 1061 ^b | 5454 | 195 (184 to 205) | -2.4 (-3.4 to -1.3) | 43 (29 to 78) |
| No NSAIDs | 70 738 (66.1) | ... | ... | 54 864 | 251 682 | 218 (216 to 220) | ... | ... |
| Total study cohort ^c | 107 092 | ... | ... | 60 974 | 275 947 | 221 (219 to 223) | ... | ... |

Abbreviations: CI, confidence interval; NNH, number needed to harm, that is, number of patients needed to treat to cause 1 additional event (death); NSAID, nonsteroidal anti-inflammatory drug; ellipses, data not available.

^aUnadjusted for confounders.

^bDeaths while receiving treatment (exposed to drug).

^cThe values do not sum because there is overlap between the exposure groups.

age for each drug. This method allowed for dosages to be changed at dispensing of a new prescription. The method has been described in detail previously.^{15,16}

From the national prescription registry, all claimed prescriptions of NSAIDs (ATC code M01A) by the study cohort were identified. The most frequently used selective COX-2 inhibitors, rofecoxib (M01AH02) and celecoxib (M01AH01), and nonselective NSAIDs, ibuprofen (M01AE01) and diclofenac (M01AB05), were analyzed separately because they represented most of the selective COX-2 inhibitors and nonselective NSAIDs used. In addition, the nonselective NSAID naproxen (M01AE02) was analyzed separately to gain further knowledge about the cardiovascular risk associated with this NSAID. Rofecoxib, celecoxib, ibuprofen, diclofenac, and naproxen were classified as low or high dosages in the analyses. The upper limit of low dosage was defined as the lower recommended daily dose for the individual NSAIDs, that is, 25 mg for rofecoxib, 200 mg for celecoxib, 1200 mg for ibuprofen, 100 mg for diclofenac, and 500 mg for naproxen. Other NSAIDs, not including glucosamine (M01AX05), were categorized as 1 group in the analyses, without dosage specification. We defined concomitant treatment status with the following cardiovascular drugs: angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers (ATC C09 ACEi/ARBs), β -blockers (ATC C07), and spironolactone (ATC C03D) as prescriptions claimed within 90 days after discharge, and statins (ATC C10AA) claimed within 180 days after discharge.

To quantify the severity of HF or severity of accompanying renal failure, patients were classified into 4 groups according to the mean daily dose of loop diuretics (ATC C03C) used within the first 90 days after discharge (furosemide equivalent dosage: furosemide, 40 mg = bumetanide, 1 mg): group 1, 0 to 39 mg; group 2, 40 to 80 mg; group 3, 81 to 160 mg; and group 4, more than 160 mg.^{15,17} Pharmacologically treated diabetes was identified from prescriptions of glucose-lowering medication (ATC A10) from 90 days before admission to 90 days after discharge.

COMORBIDITY

The Charlson Comorbidity Index, modified for the *International Classification of Diseases, Tenth Revision*, was used to define comorbidity (Table 1).^{18,19} The Charlson Comorbidity index was estimated at discharge and further enhanced by including diagnoses up to 1 year before the index hospitalization.

STATISTICAL ANALYSIS

Time to death, and hospitalization because of myocardial infarction (MI) or HF were estimated using Cox proportional hazards regression models, including exposure to drug of interest as time-dependent covariates in the models (ie, patients were only considered at risk when they were taking the drug). The models allowed patients to switch from 1 specific NSAID to another specific NSAID, thereby changing exposure status. The models also permitted concomitant use of different NSAIDs; however, combinations were not analyzed specifically. The Cox proportional hazards regression models were adjusted for age, sex, calendar year, duration of exposure, concomitant medical treatment, and comorbidity. The proportional hazard assumption is invalid in time-dependent proportional hazard models; however, the linearity of continuous variables and lack of interaction were tested and found valid unless otherwise indicated.

As a sensitivity analysis, we performed risk-stratified analysis by ranking the patients into tertiles according to an estimated propensity score for death within 1 year after discharge. The propensity score was estimated using logistic regression analysis conditional on baseline covariates. Furthermore, to ensure the robustness of our findings, the analyses were repeated using case-crossover models.²⁰ The case-crossover analysis includes only patients experiencing an event; however, rather than using matched control subjects, the case serves as its own control, thereby reducing the effect of unmeasured confounders. The case period was defined as 0 to 30 days before the event (death or hospitalization because of MI or HF), and control periods as 60 to 90 days and 90 to 120 days before the event.

Mortality was calculated as deaths per 1000 person-years exposed. The number needed to harm was estimated for each drug from the unadjusted mortality as number needed to harm per 1000 person-years exposed. All statistical calculations were performed using commercially available software (SAS version 9.1; SAS Institute, Inc, Cary, North Carolina).

RESULTS

A total of 107 092 patients with HF were identified and included in the study. Of these, 36 354 patients (33.9%) received at least 1 prescription of either a selective COX-2 inhibitor or a nonselective NSAID. Baseline characteristics are given in Table 1. Table 2 lists the duration of

Table 3. Hazard Ratios for Death, and Hospitalization Because of HF or AMI

| Drug | Death | | Hospitalization Because of HF | | Hospitalization Because of AMI | |
|-------------|------------------|----------------------|-------------------------------|----------------------|--------------------------------|----------------------|
| | HR (95% CI) | P Value ^a | HR (95% CI) | P Value ^a | HR (95% CI) | P Value ^a |
| Rofecoxib | | | | | | |
| Any use | 1.70 (1.58-1.82) | <.001 | 1.40 (1.26-1.55) | <.001 | 1.30 (1.07-1.59) | .01 |
| ≤25 mg/d | 1.42 (1.31-1.54) | <.001 | 1.33 (1.20-1.49) | <.001 | 1.26 (1.01-1.57) | .04 |
| >25 mg/d | 3.54 (3.12-4.02) | <.001 | 1.86 (1.46-2.35) | <.001 | 1.59 (0.97-2.61) | .07 |
| Celecoxib | | | | | | |
| Any use | 1.75 (1.63-1.88) | <.001 | 1.24 (1.12-1.39) | <.001 | 1.38 (1.13-1.69) | .001 |
| ≤200 mg/d | 1.34 (1.22-1.48) | <.001 | 1.24 (1.09-1.41) | .001 | 1.33 (1.05-1.69) | .02 |
| >200 mg/d | 2.72 (2.45-3.02) | <.001 | 1.26 (1.04-1.53) | .02 | 1.50 (1.08-2.10) | .02 |
| Ibuprofen | | | | | | |
| Any use | 1.31 (1.25-1.37) | <.001 | 1.16 (1.10-1.23) | <.001 | 1.33 (1.19-1.50) | <.001 |
| ≤1200 mg/d | 0.99 (0.94-1.04) | .65 | 1.16 (1.09-1.23) | <.001 | 1.31 (1.15-1.48) | <.001 |
| >1200 mg/d | 2.83 (2.64-3.02) | <.001 | 1.18 (1.04-1.33) | .01 | 1.47 (1.15-1.89) | .002 |
| Diclofenac | | | | | | |
| Any use | 2.08 (1.95-2.21) | <.001 | 1.35 (1.24-1.48) | <.001 | 1.36 (1.12-1.64) | .002 |
| ≤100 mg/d | 1.31 (1.20-1.42) | <.001 | 1.34 (1.21-1.48) | <.001 | 1.14 (0.91-1.43) | .26 |
| >100 mg/d | 5.54 (5.08-6.03) | <.001 | 1.42 (1.17-1.73) | .004 | 2.43 (1.74-3.40) | <.001 |
| Naproxen | | | | | | |
| Any use | 1.22 (1.07-1.39) | .004 | 1.18 (1.00-1.40) | .05 | 1.52 (1.11-2.06) | .01 |
| ≤500 mg/d | 0.88 (0.73-1.05) | .15 | 1.18 (0.97-1.44) | .10 | 1.47 (1.02-2.10) | .04 |
| >500 mg/d | 1.97 (1.64-2.36) | <.001 | 1.18 (0.88-1.57) | .27 | 1.62 (0.97-2.72) | .07 |
| Other NSAID | 1.28 (1.21-1.35) | <.001 | 1.27 (1.18-1.36) | <.001 | 1.32 (1.13-1.54) | .004 |

Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug.

^aCox proportional-hazard analysis adjusted for age, sex, year of first hospitalization because of heart failure, comorbidity, severity (loop diuretic dosage), and concomitant medical treatment.




Figure 1. Hazard ratios for death associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals.

treatment with individual drugs and median doses. The median duration of treatment of individual NSAIDs varied between 42 and 97 days (Table 2).

MORTALITY

A total of 60 974 (56.9%) patients died during the study. Mortality, absolute risk increase, and number needed to harm related to each exposure group are listed in Table 2. There was an increased risk of death associated with treatment with most NSAIDs. The increase in risk was highest for rofecoxib, celecoxib, and diclofenac. This was confirmed in multivariate Cox proportional hazards regression

analysis (Table 3 and Figure 1), with a clear dose-dependent increase in risk. Low doses of ibuprofen and naproxen were not associated with increased mortality risk, although high doses of both of these drugs were associated with an increased risk of death.

HOSPITALIZATION BECAUSE OF MI

Hospitalization because of MI occurred in 8970 patients (8.4%). An increased risk of MI was associated with treatment with both selective COX-2 inhibitors and nonselective NSAIDs (Table 3 and Figure 2), and hazard ratios were similar for all types of NSAIDs. A dose-




Figure 2. Hazard ratios for hospitalization because of acute myocardial infarction associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals.




Figure 3. Hazard ratios for hospitalization because of heart failure associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals.

dependent increase in risk of MI was evident with rofecoxib and diclofenac.

HOSPITALIZATION BECAUSE OF HF

A total of 39 984 patients (37.5%) were hospitalized because of HF. All of the drugs were associated with an increased risk of hospitalization because of HF (Table 3 and **Figure 3**). Rofecoxib was associated with the highest risk and demonstrated a dose-dependent increase in risk.

CASE-CROSSOVER ANALYSIS

Repeating the analysis using case-crossover models generated similar results (**Table 4**) as with Cox proportional hazards regression analysis.

SENSITIVITY ANALYSES

Figure 4 shows the hazard ratios for death within 1 year after discharge across tertiles of risk of death as defined

by baseline variables. The C statistic was 0.72, indicating good discriminatory power of the models to differentiate strata of risk. The increased risk associated with NSAID therapy was present at all strata.

No important interactions were noted between the different exposure groups and subgroups of patients. In particular, we analyzed subgroups of patients receiving prophylactic evidence-based pharmacotherapy (angiotensin-converting enzyme inhibitors, β -blockers, spironolactone, and statins) and found no indication for effect modification in risk associated with use of these drugs. Also, we found no interaction in risk between patients who did or did not have previous acute MI.

COMMENT

We found increased mortality and increased risk of hospitalization because of MI or HF related to NSAID use in an unselected cohort of patients discharged alive after their first hospitalization because of HF. The risk was

Table 4. Odds Ratios for Death, and Hospitalization Because of HF or AMI^a

| Drug | Death | | Hospitalization Because of HF | | Hospitalization Because of AMI | |
|-------------|-------------------|---------|-------------------------------|---------|--------------------------------|---------|
| | OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value |
| Rofecoxib | | | | | | |
| Any use | 1.62 (1.40-1.88) | <.001 | 2.39 (1.89-3.01) | <.001 | 1.39 (0.93-2.06) | .11 |
| ≤25 mg/d | 1.19 (1.01-1.40) | .03 | 2.12 (1.67-2.70) | <.001 | 1.32 (0.88-1.98) | .18 |
| >25 mg/d | 4.99 (3.65-6.84) | <.001 | 6.17 (3.22-11.82) | <.001 | 2.73 (0.66-11.32) | .17 |
| Celecoxib | | | | | | |
| Any use | 1.89 (1.60-2.23) | <.001 | 1.86 (1.45-2.40) | <.001 | 1.31 (0.85-2.04) | .23 |
| ≤200 mg/d | 1.21 (0.99-1.48) | .06 | 1.95 (1.49-2.56) | <.001 | 1.26 (0.77-2.04) | .36 |
| >200 mg/d | 4.11 (3.15-5.38) | <.001 | 1.48 (0.87-2.54) | .15 | 1.51 (0.70-3.27) | .29 |
| Ibuprofen | | | | | | |
| Any use | 1.50 (1.36-1.65) | <.001 | 1.41 (1.24-1.61) | <.001 | 1.47 (1.15-1.88) | .002 |
| ≤1200 mg/d | 0.89 (0.79-0.99) | .04 | 1.36 (1.19-1.56) | <.001 | 1.28 (0.98-1.63) | .07 |
| >1200 mg/d | 6.43 (5.26-7.86) | <.001 | 1.86 (1.33-2.60) | .003 | 4.51 (2.28-8.91) | <.001 |
| Diclofenac | | | | | | |
| Any use | 2.50 (2.21-2.82) | <.001 | 1.97 (1.64-2.34) | <.001 | 1.64 (1.16-2.30) | .005 |
| ≤100 mg/d | 1.21 (1.04-1.40) | .01 | 1.85 (1.52-2.25) | <.001 | 1.18 (0.81-1.72) | .38 |
| >100 mg/d | 14.69 (10.9-19.7) | <.001 | 2.90 (1.81-4.64) | <.001 | 9.10 (3.45-23.98) | <.001 |
| Naproxen | | | | | | |
| Any use | 1.20 (0.91-1.58) | .12 | 1.02 (0.72-1.46) | .90 | 1.31 (0.64-2.71) | .05 |
| ≤500 mg/d | 0.84 (0.60-1.17) | .29 | 1.03 (0.69-1.53) | .89 | 1.31 (0.56-3.05) | .54 |
| >500 mg/d | 2.35 (1.51-3.65) | .002 | 1.01 (0.53-1.89) | .98 | 1.33 (0.39-4.50) | .65 |
| Other NSAID | 1.29 (1.15-1.44) | <.001 | 1.68 (1.44-1.97) | <.001 | 1.56 (1.16-2.08) | .003 |

Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; HF, heart failure; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.

^aConditional logistic regression by the case-crossover design. Case period, 0 to 30 days before event; control periods, 60 to 90 days and 90 to 120 days before event.

increased for all of the selective COX-2 inhibitors and diclofenac, and for ibuprofen and naproxen in high dosages. A causative relationship was indicated by a dose-dependent increase in risk. The extensive absolute increase in risk of 11.1% for rofecoxib, 7% for celecoxib, and 9% for diclofenac, and the low number needed to harm are worrisome, in particular because 34% of patients with HF received a prescription for an NSAID. Apparently awareness is low among physicians concerning international clinical recommendations that discourage use of NSAIDs in patients with HF.

Most of the current knowledge of the cardiovascular risk with use of NSAID therapy is based on post hoc analyses and analysis of subgroups of patients from studies designed to examine noncardiovascular diseases^{1,5,6,21,22}; however, to our knowledge, with the exception of 1 study,⁷ no clinical trials have primarily been designed to address the cardiovascular risk with use of NSAIDs. Focus has primarily been on the COX-2 inhibitors, whereas the cardiovascular risk with use of nonselective NSAIDs is estimated primarily from observational studies and meta-analyses.^{3,4,8-11,23} In the future, the discrepancy in results of randomized trials and observational studies may be resolved by the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen (PRECISION) Trial, which currently is recruiting patients.²⁴

The biological effects of NSAIDs have been discussed in detail previously.²⁵ In brief, NSAIDs inhibit cyclooxygenase, which by 2 separate pathways promotes the synthesis of thromboxanes (COX-1) and prostaglandins (COX-2) from arachidonic acid. It has been proposed that excessive cardiovascular risk with use of NSAIDs is due primarily to an imbalance in inhibition of these path-

ways. The various NSAIDs have different abilities for inhibition of COX-1 and COX-2, and the more COX-2-selective NSAIDs seem to have a more cardiotoxic effect. Furthermore, there seems to be marked interindividual variability in the response to selective COX-2 inhibition, which might interfere with the susceptibility to cardiovascular risk,²⁶ which also is more pronounced in patients with established cardiovascular disease.^{7,10,27-29} Focus has primarily been on the increased thromboembolic risk, although other properties of NSAIDs could influence the risk in patients with HF. NSAIDs influence renal function and the regulation of fluid balance, causing fluid retention and worsening of HF, in addition to promoting increased risk of hypertension and destabilization of blood pressure.³⁰ Animal models have demonstrated that COX-2 inhibition can induce structural changes in the myocardium³¹ and enhance left ventricular remodeling, impair systolic function, and increase mortality after MI.³² Regulation of fluid balance and blood pressure is of particular importance in chronic HF; thus, NSAIDs might tip the balance and worsen HF, and in the worst-case scenario, lead to a fatal outcome. A causative relationship between NSAID use and cardiovascular risk in patients with established HF is, therefore, highly plausible.

Agreement is general regarding increased cardiovascular risk with the selective COX-2 inhibitor rofecoxib, whereas the risk with celecoxib has been debated.* We have previously found increased risk with celecoxib in a cohort of patients after MI,¹⁰ and Brophy et al²⁷ demonstrated that celecoxib was harmful only in patients who had had an MI.²⁷ Hudson et al^{28,36} found that celecoxib

*References 3, 6, 9-11, 21, 23, 27, 28, 33-35.

increased the risk of hospitalization because of HF similarly to conventional NSAIDs.^{28,36} In 2 meta-analyses, McGettigan and Henry¹¹ and Kearney et al²³ did not find increased cardiovascular risk with celecoxib therapy. Hence, it seems that celecoxib may be particularly harmful in patients with established cardiovascular disease. Among the conventional nonselective NSAIDs, the cardiovascular risk with naproxen has been much debated, and some reports have suggested that naproxen was cardioprotective because of its similar ability as aspirin to inhibit COX-1.³⁷⁻³⁹ In the present study, naproxen at high dosages was associated with increased mortality and increased risk of hospitalization because of MI and HF. This is in accordance with several other reports,^{4,9,34} whereas others have not been able to demonstrate increased risk with use of naproxen.^{11,23} However, considering the present results along with the existing evidence, physicians must exert caution in using naproxen in patients with HF, as with other NSAIDs. It is intriguing that the NSAID associated with the highest risk was diclofenac, whose COX-2 selectivity is similar to that of celecoxib.²⁵ Increased cardiovascular risk with diclofenac has been demonstrated previously,^{10,11,23} and the present study extends this finding to patients with HF. Particularly worrisome is that diclofenac is a widely used NSAID, and in many countries it is dispensed OTC, which might be misinterpreted to indicate that diclofenac is a harmless drug. Another common NSAID with OTC status is ibuprofen, which we found harmful in high dosages. Ibuprofen can interact with aspirin by competitively inhibiting COX-1 in the thrombocytes. The inhibition by ibuprofen is reversible, whereas aspirin irreversibly inhibits COX-1; hence, ibuprofen can diminish the cardioprotection of aspirin if taken simultaneously.⁴⁰⁻⁴² Previous study results have reported an increased risk of hospitalization because of HF associated with NSAID treatment.^{28,29,35,36} The present study demonstrates increased mortality and individual differences in risk between the various NSAIDs and dosages. Most patients used NSAIDs for a short time, shortest for the COX-2 inhibitors and diclofenac, which indicates relatively acute cardiotoxic effects of these drugs and is in accord with other reports.^{10,43} We found no indication for effect modification by use of evidence-based pharmacotherapy at baseline for the risk exerted by NSAID treatment. Thus, NSAIDs should be avoided in all patients with HF, regardless of baseline pharmacotherapy.

STUDY STRENGTHS AND LIMITATIONS

The main strength of this study is that it includes complete data from an entire nation (Denmark), thus avoiding selection bias by including only subgroups of patients or patients from selected hospitals, medical centers, or health care systems. In Denmark, a government-financed health care system ensures equal access to health care for all inhabitants free. Drug expenses are partially reimbursed, and pharmacies are required to register all dispensed prescriptions in the nationwide prescription registry, ensuring complete registration. Use of OTC NSAID drugs is negligible; ibuprofen is the only NSAID with OTC status in Denmark, and only in low doses (200 mg) and in limited quan-




Figure 4. The association between drug use and risk of death according to risk subgroup. The high (>31.4%), intermediate (17.9%-31.4%), and low (<17.9%) mortality risk categories represent tertiles of predicted 1-year mortality risk in a propensity-based analysis. NSAIDs indicates nonsteroidal anti-inflammatory drugs.

tity at each dispensing. Hence, patients needing long-term treatment or higher dosages would have an incentive to get a prescription from their physician because only prescribed drugs are covered by the reimbursement policy. Ibuprofen achieved OTC status in October 2001, and in a sensitivity analysis including data only to January 1, 2001, we achieved similar results (data not shown). Thus, OTC use of ibuprofen is unlikely to have major, if any, effects on the present results.

The main limitation of the present study is its observational design. The discharge coding diagnosis of HF has been validated in the Danish National Patient Registry and, in accord with other studies, found to have high specificity but low sensitivity.^{44,45} Thus, the discharge coding diagnosis of HF is suitable to correctly identify patients with HF but not for investigating the prevalence or incidence of HF in a population. Another important limitation is the lack of detailed information about important prognostic factors such as left ventricular ejec-

tion fraction, New York Heart Association classification, smoking, and lipid levels. Although appropriate adjustments were made for comorbidity, the effect of unmeasured confounders can never be fully excluded. In addition, the indication for starting NSAID therapy for each patient is lacking. Thus, the disease or the pain-eliciting condition being treated with an NSAID could indicate a status with increased risk for the patient being treated. However, considering current recommendations that discourage NSAIDs in HF, a channeling bias toward less use of NSAIDs in patients at high risk could be expected because physicians could be more reluctant to use NSAIDs in patients with more severe HF. Comparing baseline characteristics among exposure groups (Table 1), this might be the case because there were fewer patients in severity group 4 using NSAIDs compared with severity groups 1 and 2. The propensity-based risk-stratified analysis yielded similar hazard ratios across all risk groups (Figure 4), with a dose-dependent response (data not shown), and the case-crossover models generated similar results. Thus, confounding by indication alone does not explain the increased risk of NSAID use in this cohort. Furthermore, the difference in risk across different NSAIDs and a dose-dependent increase in risk further supports a causative relationship.

CONCLUSIONS

Treatment with NSAIDs, both selective COX-2 inhibitors and nonselective NSAIDs, in patients with chronic HF is associated with increased mortality and cardiovascular morbidity, with a dose-dependent response. Therefore, patients with HF should, if possible, avoid using any NSAIDs at any dosage for most NSAIDs and at high dosages for ibuprofen and naproxen. Treatment in patients with pain conditions relieved by these drugs should be based on a medically competent evaluation of the benefits vs risks of treatment. Patients who depend on using these drugs should preferably use the NSAIDs that are more COX-1 selective, in as low dosages and for as short a period as possible.

Further research is required to establish the cardiovascular risk associated with all NSAIDs in subgroups of patients with cardiovascular disease, particularly if a low dosage with analgesic effect can be used without increased risk. In the meantime, because of the accumulating evidence, general awareness is required among physicians, health care authorities, and the general public about the potential cardiovascular risk of NSAIDs, in particular in patients with established cardiovascular disease or at increased cardiovascular risk.

Accepted for Publication: July 14, 2008.

Author Affiliations: Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark (Drs Gislason, Abildstrom, Schramm, Hansen, Sørensen, Folke, Buch, and Torp-Pedersen, and Mr Fosbøl); National Institute of Public Health (Drs J. N. Rasmussen, Abildstrom, Schramm, and S. Rasmussen), Departments of Clinical Pharmacology (Dr Poulsen) and Cardiology (Dr Køber), Rigshospitalet-Copenhagen Uni-

versity Hospital, Copenhagen, Denmark; Faculty of Health Sciences (Drs Poulsen, Køber, and Torp-Pedersen) and Institute of Public Health Research (Ms Madsen), University of Copenhagen, Copenhagen; and Department of Medicine, Roskilde County Hospital, Køge (Dr Gadsbøll), Denmark.

Correspondence: Gunnar H. Gislason, MD, PhD, Department of Cardiology, Gentofte University Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark (gg@heart.dk).

Author Contributions: Dr Gislason had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Gislason, Abildstrom, Poulsen, Madsen, and Torp-Pedersen. *Acquisition of data:* Gislason, J. N. Rasmussen, Abildstrom, Madsen, and Torp-Pedersen. *Analysis and interpretation of data:* Gislason, J. N. Rasmussen, Abildstrom, Schramm, Hansen, Fosbøl, Sørensen, Folke, Buch, Gadsbøll, S. Rasmussen, Poulsen, Køber, Madsen, and Torp-Pedersen. *Drafting of the manuscript:* Gislason. *Critical revision of the manuscript for important intellectual content:* Gislason, J. N. Rasmussen, Abildstrom, Schramm, Hansen, Fosbøl, Sørensen, Folke, Buch, Gadsbøll, S. Rasmussen, Poulsen, Køber, Madsen, and Torp-Pedersen. *Statistical analysis:* Gislason, Abildstrom, Fosbøl, S. Rasmussen, Køber, Madsen, and Torp-Pedersen. *Obtained funding:* Gislason, Køber, Madsen, and Torp-Pedersen. *Administrative, technical, and material support:* Gislason, J. N. Rasmussen, Folke, Poulsen, and Torp-Pedersen. *Study supervision:* Abildstrom, Poulsen, Madsen, and Torp-Pedersen. **Financial Disclosure:** None reported.

REFERENCES

1. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N Engl J Med.* 2000;343(21):1520-1528.
2. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA.* 2001;286(8):954-959.
3. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. *Lancet.* 2004;364(9450):2021-2029.
4. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. *Lancet.* 2005;365(9458):475-481.
5. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med.* 2005;352(11):1071-1080.
6. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med.* 2005;352(11):1092-1102.
7. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med.* 2005;352(11):1081-1091.
8. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. *BMJ.* 2005;330(7504):1366-1373.
9. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. *Arch Intern Med.* 2005;165(9):978-984.
10. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective

- nonsteroidal antiinflammatory drugs after acute myocardial infarction. *Circulation*. 2006;113(25):2906-2913.
11. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA*. 2006;296(13):1633-1644.
 12. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol*. 2005;46(6):e1-e82.
 13. Swedberg K, Cleland J, Dargie H, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J*. 2005;26(11):1115-1140.
 14. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*. 2007;115(12):1634-1642.
 15. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. *Circulation*. 2007;116(7):737-744.
 16. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. *Eur Heart J*. 2006;27(10):1153-1158.
 17. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. *Am J Cardiol*. 2006;97(12):1759-1764.
 18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.
 19. Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. *J Clin Epidemiol*. 2006;59(3):265-273.
 20. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol*. 1991;133(2):144-153.
 21. Solomon SD, Pfeffer MA, McMurray JJ, et al; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. *Circulation*. 2006;114(10):1028-1035.
 22. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). *PLoS Clin Trials*. 2006;1(7):e33.
 23. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. *BMJ*. 2006;332(7553):1302-1308.
 24. Pfizer. PRECISION: Prospective randomized evaluation of celecoxib integrated safety vs ibuprofen or naproxen. <http://clinicaltrials.gov/show/NCT00346216>. Accessed July 1, 2007.
 25. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. *Circulation*. 2005;112(5):759-770.
 26. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. *Gastroenterology*. 2006;130(1):55-64.
 27. Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. *Heart*. 2007;93(2):189-194.
 28. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal antiinflammatory drugs: population based study. *BMJ*. 2005;330(7504):1370-1376.
 29. Huerta C, Varas-Lorenzo C, Castellsague J, García Rodríguez LA. Non-steroidal antiinflammatory drugs and risk of first hospital admission for heart failure in the general population. *Heart*. 2006;92(11):1610-1615.
 30. Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. *Arch Intern Med*. 2005;165(5):490-496.
 31. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. *Cell Metab*. 2005;2(3):201-207.
 32. Timmers L, Sluijter JPG, Verlaan CWJ, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. *Circulation*. 2007;115(3):326-332.
 33. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study, a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA*. 2000;284(10):1247-1255.
 34. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nation-wide case-control study from Finland. *Eur Heart J*. 2006;27(14):1657-1663.
 35. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. *Lancet*. 2004;363(9423):1751-1756.
 36. Hudson M, Rahme E, Richard H, Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? *Arthritis Rheum*. 2007;57(3):516-523.
 37. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. *Arch Intern Med*. 2002;162(10):1099-1104.
 38. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. *Arch Intern Med*. 2002;162(10):1111-1115.
 39. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. *Arch Intern Med*. 2002;162(10):1105-1110.
 40. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med*. 2001;345(25):1809-1817.
 41. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction [published correction appears in *J Rheumatol*. 2005;32(11):2280]. *J Rheumatol*. 2005;32(8):1589-1593.
 42. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high-risk patients with osteoarthritis treated with ibuprofen, naproxen, or lumiracoxib. *Ann Rheum Dis*. 2007;66(6):764-770.
 43. Lévesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. *CMAJ*. 2006;174(11):1563-1569.
 44. Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. *Eur J Heart Fail*. 2008;10(7):658-660.
 45. Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. *Med Care*. 2005;43(2):182-188.
 46. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. *J Clin Invest*. 2006;116(1):4-15.